Risk of subsequent primary thyroid cancer after another malignancy: Latency trends in a population-based study

Annals of Surgical Oncology

Volumn 19, Issue 6, 2012, Pages 1887-1896

  Lal, Geeta ^a   Groff, Megan ^a   Howe, James R ^a   Weigel, Ronald J ^a   Sugg, Sonia L ^a   Lynch, Charles F ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; COLORECTAL CANCER; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKEMIA; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; POPULATION RESEARCH; PRIMARY TUMOR; PROSTATE CANCER; RISK ASSESSMENT; SUBSEQUENT PRIMARY THYROID CANCER; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TREND STUDY; UTERUS CANCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RISK FACTORS; SEER PROGRAM; THYROID NEOPLASMS; UNITED STATES; YOUNG ADULT;

EID: 84865127305     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2193-2     Document Type: Article

References (21)

1. Howlader N, Krapcho M, Neyman N, et al., eds. SEER cancer statistics review, 1975-2008. Bethesda, MD: National Cancer Institute, 2010. http://seer.cancer.gov/csr/1975-2008/.
2. Brown P, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 2008;93:504-15. (Pubitemid 351240823)
3. Canchola AJ, Horn-Ross PL, Purdie DM. Risk of second primary malignancies in women with papillary thyroid cancer. Am J Epidemiol. 2006;163:521-7.
4. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003;89: 1638-44. (Pubitemid 37464133)
5. Berthe E, Henry-Amar M, Michels JJ, et al. Risk of second primary cancer following differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2004;31:685-91. (Pubitemid 38647907)
6. Subramanian S, Goldstein DP, Parlea L, et al. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid. 2007;17:1277-88.
7. Sandeep TC, Strachan MW, Reynolds RM, et al. Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab. 2006;91:1819-25.
8. Ronckers CM, McCarron P, Ron E. Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer. 2005;117:281-8. (Pubitemid 41377449)
9. Chuang SC, Hashibe M, Yu GP, et al. Radiotherapy for primary thyroid cancer as a risk factor for second primary cancers. Cancer Lett. 2006;238:42-52. (Pubitemid 43851143)
10. Taylor AJ, Croft AP, Palace AM, et al. Risk of thyroid cancer in survivors of childhood cancer: results from the British Childhood Cancer Survivor Study. Int J Cancer. 2009;125:2400-5.
11. Armstrong GT, Stovall M, Robison LL. Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the Childhood Cancer Survivor Study. Radiat Res. 2010;174:840-50.
12. Bhatti P, Veiga LH, Ronckers CM, et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the Childhood Cancer Survivor Study. Radiat Res. 2010;174:741-52.
13. National Cancer Institute. Surveillance, Epidemiology, and End Results. SEER registry groupings for analyses. http://www.seer. cancer.gov/registries/ terms.html.
14. Hedinger C, Williams ED, Sobin LH. The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer. 1989;63:908-11. (Pubitemid 19063200)
15. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006;49:798-805.
16. Malchoff CD, Sarfarazi M, Tendler B, et al. Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab. 2000;85:1758-64. (Pubitemid 32269272)
17. Richards ML. Familial syndromes associated with thyroid cancer in the era of personalized medicine. Thyroid. 2010;20:707-13.
18. Cybulski C, Gorski B, Huzarski T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet. 2004;75:1131-5. (Pubitemid 39532081)
19. Kikuchi S, Perrier ND, Ituarte P, Siperstein AE, Duh QY, Clark OH. Latency period of thyroid neoplasia after radiation exposure. Ann Surg. 2004;239:536-43. (Pubitemid 38372770)
20. Liu H, Hemminki K, Sundquist J. Renal cell carcinoma as first and second primary cancer: etiological clues from the Swedish Family-Cancer Database. J Urol. 2011;185:2045-9.
21. Sawka AM, Thabane L, Parlea L, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid. 2009;19:451-7.